Concord Biotech gets final approval from USFDA for marketing Teriflunomide Tablets

09 Apr 2025 Evaluate

Concord Biotech has been granted final approval from the United States Food and Drug Administration (USFDA) for marketing its Teriflunomide Tablets, 7 mg and 14 mg. Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis.

This approval reinforces the company’s capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market. According to IQVIA, the market size of Teriflunomide tablets is around $402 million in the US, and the global market size is around $908 million, indicating significant opportunities for expansion in the US and the global market.

Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.


Concord Biotech Share Price

1404.05 1.00 (0.07%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×